Objectives, structure and design of the Study

Study design

STEP I: Induction

STEP II: Randomization

Patients achieving at least PR will be randomized either to RIT (arm A) or ASCT (arm B)

STEP III: Stem cell mobilization

All patients will receive Ara-C and rituximab, followed by stem cell collection (aim of collecting 6x106 CD34+ cells/kg) A second mobilization with plerixafor will be allowed for patients that experience a mobilization failure after Ara-C (both arms).

STEP IV: Consolidation

ARM A (RIT): infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging.